Abstract:
The article is dedicated to development of homeostatic criteria of efficacy and safety
of drugs combinations “lisinopril, bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic
acid”. These criteria are based on study of homeostatic shifts and their association with
clinical and laboratory parameters on elder patients with arterial hypertension (AH) II, III
stage combined with coronary artery disease (CAD).
Complex clinical, biochemical, biophysical and instrumental investigation was
performed in 67 patients with AH II, III stage combined with CAD.
On the grounds of developed criteria was established that for patients with AH II and
CAD is not recommended combination “lisinopril, acetylsalicylic acid” and for those ones
with AH III and CAD prohibited combinations “lisinopril, bisoprolol, acetylsalicylic acid”
and “lisinopril, bisoprolol, indapamide, isosorbide dinitrate, acetylsalicylic acid” in order to
prevent development of drug induced renal dysfunction.
It was also determined safety of combinations “lisinopril, bisoprolol, acetylsalicylic
acid”; “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” for patients with AH II and
CAD and “lisinopril, bisoprolol, indapamide, acetylsalicylic acid” for those ones with AH III
and CAD.
